June 18, 2018 07:25 AM EDTUpdated May 26, 08:50 PM

Solid Bio is back in business after the FDA lifts clinical hold on Duchenne MD gene therapy

John Carroll

Editor & Founder

Three months after the FDA dropped a clinical hold on Solid Biosciences $SLDB over safety concerns related to their gene therapy for Duchenne muscular dystrophy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Solid Bio is back in business after the FDA lifts clinical hold on Duchenne MD gene therapy

John Carroll

Editor & Founder

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers

Sol­id Bio is back in busi­ness af­ter the FDA lifts clin­i­cal hold on Duchenne MD gene ther­a­py

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Solid Bio is back in business after the FDA lifts clinical hold on Duchenne MD gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers